How to buy ESSA Pharma stock | $8

ESSA Pharma Inc is a biotechnology business based in the US. ESSA Pharma shares (EPIX) are listed on the NASDAQ and all prices are listed in US Dollars. ESSA Pharma employs 25 staff and has a market cap (total outstanding shares value) of USD$337.7 million.

How to buy shares in ESSA Pharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ESSA Pharma. Find the stock by name or ticker symbol: EPIX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ESSA Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$8, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ESSA Pharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ESSA Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ESSA Pharma share price

Use our graph to track the performance of EPIX stocks over time.

ESSA Pharma shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$8
52-week range	USD$3 - USD$10.25
50-day moving average	USD$6.9971
200-day moving average	USD$6.608
Wall St. target price	USD$0.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.747

Buy ESSA Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ESSA Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ESSA Pharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ESSA Pharma price performance over time

Historical closes compared with the close of $8 from 2020-12-18

1 week (2021-01-15)	-50.03%
1 month (2020-12-23)	-16.67%
3 months (2020-10-22)	24.03%
6 months (2020-07-22)	25.00%

1 year (2020-01-22)	41.84%
2 years (2019-01-22)	100.00%
3 years (2018-01-22)	3,536.36%
5 years (2016-01-21)	130.55%

ESSA Pharma financials

Gross profit TTM	USD$0
Return on assets TTM	-21.75%
Return on equity TTM	-36.57%
Profit margin	0%
Book value	$2.471
Market capitalisation	USD$337.7 million

TTM: trailing 12 months

Shorting ESSA Pharma shares

There are currently 6,083 ESSA Pharma shares held short by investors – that's known as ESSA Pharma's "short interest". This figure is 47.2% down from 11,527 last month.

There are a few different ways that this level of interest in shorting ESSA Pharma shares can be evaluated.

ESSA Pharma's "short interest ratio" (SIR)

ESSA Pharma's "short interest ratio" (SIR) is the quantity of ESSA Pharma shares currently shorted divided by the average quantity of ESSA Pharma shares traded daily (recently around 33794.444444444). ESSA Pharma's SIR currently stands at 0.18. In other words for every 100,000 ESSA Pharma shares traded daily on the market, roughly 180 shares are currently held short.

However ESSA Pharma's short interest can also be evaluated against the total number of ESSA Pharma shares, or, against the total number of tradable ESSA Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ESSA Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ESSA Pharma shares in existence, roughly 0 shares are currently held short) or 0.0006% of the tradable shares (for every 100,000 tradable ESSA Pharma shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ESSA Pharma.

Find out more about how you can short ESSA Pharma stock.

ESSA Pharma share dividends

We're not expecting ESSA Pharma to pay a dividend over the next 12 months.

Have ESSA Pharma's shares ever split?

ESSA Pharma's shares were split on a 1:20 basis on 25 April 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ESSA Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for ESSA Pharma shares which in turn could have impacted ESSA Pharma's share price.

ESSA Pharma share price volatility

Over the last 12 months, ESSA Pharma's shares have ranged in value from as little as $3 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ESSA Pharma's is 1.5198. This would suggest that ESSA Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ESSA Pharma overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Frequently asked questions

• What percentage of ESSA Pharma is owned by insiders or institutions?

  Currently 8.713% of ESSA Pharma shares are held by insiders and 64.044% by institutions.

• How many people work for ESSA Pharma?

  Latest data suggests 25 work at ESSA Pharma.

• When does the fiscal year end for ESSA Pharma?

  ESSA Pharma's fiscal year ends in September.

• Where is ESSA Pharma based?

  ESSA Pharma's address is: 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5

• What is ESSA Pharma's ISIN number?

  ESSA Pharma's international securities identification number is: CA29668H7085

• What is ESSA Pharma's CUSIP number?

  ESSA Pharma's Committee on Uniform Securities Identification Procedures number is: 29668H104